Dectrocel Raises Rs 4 Crore to Expand AI Diagnostics India, Southeast Asia

Dectrocel, a health-tech startup specializing in AI-powered diagnostic solutions, has raised Rs 4 crore in a funding round led by IAN Group-powered BioAngels with participation from PadUp Ventures and Vinners. The company’s flagship product, DecXpert, is one of only three AI-based diagnostic tools approved by India's Central Drugs Standard Control Organization for clinical use, delivering chest X-ray and CT-scan interpretations that are 10 times faster and 98% accurate. This innovation addresses the critical shortage of radiologists in India, particularly in tier-2 and smaller cities, where diagnosis delays and error rates are significant. The funding will be used to scale commercial operations across India, enhance the AI technology, expand into international markets like Southeast Asia, and accelerate the launch of new diagnostic modules for CT/MRI/PET-CT and Hepato-Pancreatico-Biliary diseases. Founded by experts with backgrounds in AI, infectious diseases, public health, and data science, Dectrocel aims to democratize access to expert-level diagnostics and reduce diagnostic errors and delays. The startup plans to penetrate India's Rs 1,000 crore digital X-ray market and partner with OEM networks to expand deployment.